Hot Features
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunot... Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -2.53164556962 | 1.58 | 1.58 | 1.47 | 488 | 1.54623306 | CS |
| 4 | -0.165 | -9.67741935484 | 1.705 | 1.812 | 1.36 | 1013 | 1.59526517 | CS |
| 12 | 1.533114 | 22264.2172524 | 0.006886 | 1.99 | 0.0066 | 8549 | 0.31358044 | CS |
| 26 | 1.53138 | 17765.4292343 | 0.00862 | 1.99 | 0.003 | 164323 | 0.01211987 | CS |
| 52 | 1.5303 | 15776.2886598 | 0.0097 | 1.99 | 0.003 | 161518 | 0.01010418 | CS |
| 156 | 1.5269 | 11655.7251908 | 0.0131 | 1.99 | 0.0013 | 217513 | 0.01481982 | CS |
| 260 | 1.455 | 1711.76470588 | 0.085 | 1.99 | 0.0013 | 349166 | 0.03992517 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.